The treatment of cerebral palsy: What we know, what we don't know.
The treatment of cerebral palsy is directed at repair of the injured brain and at the management of the impairments and disabilities resulting from developmental brain injury. Currently, there are no clinically meaningful interventions that can successfully repair existing damage to the brain areas that control muscle coordination and movement. However, several interventions are available to diminish the degree of impairment (eg, muscle spasticity) and to increase participation in activities of daily living. Data on treatment compatible with evidence-based medicine are now being collected.
Goldstein
Murray
M
UCP Research and Educational Foundation, Washington, DC 20036, USA. mgoldstein@upc.org
D000203:Activities of Daily Living; D001418:Baclofen / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D001921:Brain / Q000503:physiopathology; D002547:Cerebral Palsy / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D000529:Complementary Therapies; D004298:Dopamine / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009128:Muscle Spasticity; D009465:Neuromuscular Agents / Q000627:therapeutic use; D009473:Neuronal Plasticity; D026741:Physical Therapy Modalities; D019051:Rhizotomy; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
D009125:Muscle Relaxants, Central; D009465:Neuromuscular Agents; D007980:Levodopa; D019274:Botulinum Toxins, Type A; D001418:Baclofen; D004298:Dopamine